ImmuCell Corporation
ICCC
$6.52
$0.345.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.16% | 52.10% | 11.40% | 54.92% | 110.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.16% | 52.10% | 11.40% | 54.92% | 110.58% |
| Cost of Revenue | -5.02% | 36.28% | 7.23% | 70.46% | 57.74% |
| Gross Profit | 46.12% | 81.46% | 25.00% | 17.88% | 663.10% |
| SG&A Expenses | 11.00% | 16.41% | 2.99% | 27.05% | -7.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.04% | 20.64% | 0.09% | 41.81% | 32.53% |
| Operating Income | 472.41% | 315.82% | 51.44% | -6.29% | 86.70% |
| Income Before Tax | 431.94% | 145.73% | 25.47% | -11.04% | 81.13% |
| Income Tax Expenses | 46.15% | 361.54% | 550.00% | -13.33% | -13.33% |
| Earnings from Continuing Operations | 430.44% | 145.15% | 25.35% | -11.01% | 81.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 430.44% | 145.15% | 25.35% | -11.01% | 81.09% |
| EBIT | 472.41% | 315.82% | 51.44% | -6.29% | 86.70% |
| EBITDA | 388.45% | 757.96% | 120.72% | -15.48% | 122.96% |
| EPS Basic | 385.13% | 139.16% | 29.18% | -10.11% | 81.09% |
| Normalized Basic EPS | 303.13% | 231.64% | 49.10% | -9.08% | 81.08% |
| EPS Diluted | 366.67% | 138.40% | 25.80% | -11.11% | 80.00% |
| Normalized Diluted EPS | 303.13% | 231.64% | 49.10% | -9.08% | 81.08% |
| Average Basic Shares Outstanding | 15.87% | 15.29% | 5.39% | 0.81% | 0.05% |
| Average Diluted Shares Outstanding | 15.87% | 15.29% | 5.39% | 0.81% | 0.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |